METHODS: Women who received elagolix 300 mg twice-daily with add-back (estradiol 1
mg/norethindrone acetate 0.5 mg once-daily [E2/NETA]) or elagolix alone in the preceding …

Background Uterine fibroids are hormone-responsive neoplasms that are associated with
heavy menstrual bleeding. Elagolix, an oral gonadotropin-releasing hormone antagonist …

What is this summary about? This is a summary of research studies (known as clinical trials)
called LIBERTY 1 and LIBERTY 2. The LIBERTY 1 and LIBERTY 2 studies looked at how …

Background Elagolix is effective and safe for treating menorrhagia in women with uterine
fibroid. However, it is reported to be associated with hypoestrogenism that can be alleviated …

METHODS: This double-blind, randomized, placebo-controlled, parallel group study
evaluated the efficacy and safety of 6 months of treatment in 2 cohorts, with four arms/cohort …

METHODS: These were two replicate, investigational, double-blind, randomized, placebo-
controlled, 6-month, phase 3 studies (Elaris UF-1 and Elaris UF-2) where patients were …

Novel gonadotrophin releasing hormone (GnRH) antagonist treatments have recently been
developed in combination with hormonal add‐back therapy, as an oral treatment option for …

Objective To review data of elagolix plus estradiol and norethindrone acetate as add-back
therapy for the treatment of heavy menstrual bleeding (HMB) in premenopausal women with …

Introduction Uterine fibroids (UF) are benign tumors common in premenopausal women,
with strong impact on the health-care systems. For many years, surgery represented the only …

Women with uterine fibroids who took relugolix combination therapy experienced less
menstrual bleeding and pain while avoiding bone density loss and the hot flashes …